evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,257 questions · 1,337 findings · 183 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 175 · 13.1%GRADE not reported 212 · 15.9%Very low 286 · 21.4%Low 341 · 25.5%Moderate 254 · 19%High 69 · 5.2%

Intervention not reported

Clinically apparent hepatitis A (multiple doses) low risk of bias Dienstag 1999 · patients with preventing hepatitis A.

The intervention leads to lower clinically apparent hepatitis A (multiple doses) low risk of bias… (high certainty).

1 finding from 1 review

Intervention not reported

Clinically apparent hepatitis A (multiple doses) all included trials Dienstag 1999 · patients with preventing hepatitis A.

The intervention probably leads to lower clinically apparent hepatitis A (multiple doses) all included trials… (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Progression‐free survival (PSF) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower progression‐free survival (at 24 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with newly diagnosed multiple myeloma ineligible for transplant
1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Mortality within the longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower on‐study mortality (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Proportion of participants with relapse‐free survival at ≥ 12 months · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

New or enlarging T2‐hyperintense lesions · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

The review found no eligible studies for this question.

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Leaving the study early · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower dropouts compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Sustained disease progression‐free survival · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).

1 finding from 1 review